Login / Signup

Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.

Tom EwenAkhtar HusainNiki StefanosPaul BarrettClaire JonesTom NessAnna LongStuart HorswellHelen BosomworthJoe LowensteinGrant RichardsonDavid SwanAshleigh McConnellAidan RoseTom AndrewNick ReynoldsJosep MalvehyChristina CarreraLlucia AlsoSonia MailerTom HelmLiang DingPaul BognerSebastian PodlipnikSusana Puig SardàGrant A McArthurGyorgy ParaghMarie LabusPhilip SloanJane L ArmstrongPenny E Lovat
Published in: The British journal of dermatology (2023)
These data provide further evidence validating AMBLor as a prognostic biomarker to identify non-ulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.
Keyphrases
  • skin cancer
  • electronic health record
  • big data
  • machine learning
  • wound healing
  • artificial intelligence